Etrolizumab Placebo

OTHER2 trials

Sponsors

Hoffmann-La Roche

Conditions

Ulcerative Colitis

Phase 3

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

CompletedNCT02163759

Hoffmann-La RocheUlcerative Colitis

Start: 2014-11-04End: 2020-03-19Updated: 2021-07-23

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

CompletedNCT02171429

Hoffmann-La RocheUlcerative Colitis

Start: 2014-11-14End: 2020-05-25Updated: 2021-07-23

Related Papers

P0586 Indirect Comparison of Afimkibart and Adalimumab Treatment Effects in Patients with Ulcerative Colitis Using Data from TUSCANY-2 and HIBISCUS

Journal of Crohn s and Colitis2026-01-01

P098 The Endoscopic Severity Score Map (ESSM): An Artificial Intelligence scoring system providing accurate, objective and localised measurements of endoscopic disease severity in ulcerative colitis

Journal of Crohn s and Colitis2024-01-01

P206 Artificial Intelligence reproduces central reading for automated scoring of colonoscopies from multiple clinical trials in Ulcerative Colitis

Journal of Crohn s and Colitis2023-01-30

Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.

2021-11-1774 citations

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.

2020-05-2269 citations

Antibodies to watch in 2020.

2020-01-01328 citations